journal article·2017-08-09Open access

Simultaneous Delivery of Multiple Antibacterial Agents from Additively Manufactured Porous Biomaterials to Fully Eradicate Planktonic and Adherent Staphylococcus aureus

S. Bakhshandeh, Z. Gorgin Karaji, K. Lietaert, A. C. Fluit, C. H. E. Boel, H. C. Vogely, T. Vermonden, W. E. Hennink, H. Weinans, A. A. Zadpoor, S. Amin Yavari

Abstract

Implant-associated infections are notoriously difficult to treat and may even result in amputation and death. The first few days after surgery are the most critical time to prevent those infections, preferably through full eradication of the micro-organisms entering the body perioperatively. That is particularly important for patients with a compromised immune system such as orthopedic oncology patients, as they are at higher risk for infection and complications. Full eradication of bacteria is, especially in a biofilm, extremely challenging due to the toxicity barrier that prevents delivery of high doses of antibacterial agents. This study aimed to use the potential synergistic effects of multiple antibacterial agents to prevent the use of toxic levels of these agents and achieve full eradication of planktonic and adherent bacteria. Silver ions and vancomycin were therefore simultaneously delivered from additively manufactured highly porous titanium implants with an extremely high surface area incorporating a bactericidal coating made from chitosan and gelatin applied by electrophoretic deposition (EPD). The presence of the chitosan/gelatin (Ch+Gel) coating, Ag, and vancomycin (Vanco) was confirmed by X-ray photoelectron spectroscopy (XPS) and Fourier transform infrared spectroscopy (FTIR). The release of vancomycin and silver ions continued for at least 21 days as measured by inductively coupled plasma (ICP) and UV-spectroscopy. Antibacterial behavior against Staphylococcus aureus, both planktonic and in biofilm, was evaluated for up to 21 days. The Ch+Gel coating showed some bactericidal behavior on its own, while the loaded hydrogels (Ch+Gel+Ag and Ch+Gel+Vanco) achieved full eradication of both planktonic and adherent bacteria without causing significant levels of toxicity. Combining silver and vancomycin improved the release profiles of both agents and revealed a synergistic behavior that further increased the bactericidal effects.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Orthopedic Infections and Treatments · Bacterial biofilms and quorum sensing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomechanical Engineering, Delft University of Technology, 2628 CD Delft, The Netherlands

Department of Mechanical Engineering, Kermanshah University of Technology, Kermanshah, Iran

3D Systems - LayerWise NV, 3001 Leuven, Belgium

Department of Metallurgy and Materials Engineering, KU Leuven, 3000 Leuven, Belgium

Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, 3512 JE Utrecht, The Netherlands

Funding

European Regional Development Fund · Fonds Wetenschappelijk Onderzoek

References (49)

Show source-provided references
1. 10.1016/j.ajic.2009.10.00110.1016/j.ajic.2009.10.001 ↗
2. 10.1056/NEJMra04018110.1056/NEJMra040181 ↗
3. 10.1086/32186310.1086/321863 ↗
4. Steckelberg J. M. · 2000
5. 10.22203/eCM.v029a1110.22203/eCM.v029a11 ↗
6. 10.1002/jor.2229310.1002/jor.22293 ↗
7. 10.1016/j.actbio.2011.01.03710.1016/j.actbio.2011.01.037 ↗
8. 10.1089/ten.tea.2013.018110.1089/ten.tea.2013.0181 ↗
9. 10.1111/j.1600-0501.2011.02383.x10.1111/j.1600-0501.2011.02383.x ↗
10. 10.3390/ma804187110.3390/ma8041871 ↗
11. Gibson L. J. · 1999
12. 10.1016/S1359-6462(01)01132-010.1016/S1359-6462(01)01132-0 ↗
13. 10.1016/j.biomaterials.2005.12.00210.1016/j.biomaterials.2005.12.002 ↗
14. 10.1016/j.biomaterials.2014.04.05410.1016/j.biomaterials.2014.04.054 ↗
15. 10.1016/j.biomaterials.2017.02.03010.1016/j.biomaterials.2017.02.030 ↗
16. 10.1021/acsami.6b0315210.1021/acsami.6b03152 ↗
17. 10.1128/AAC.01568-1210.1128/AAC.01568-12 ↗
18. 10.2147/IJN.S4928410.2147/IJN.S49284 ↗
19. 10.1016/j.nano.2007.02.00110.1016/j.nano.2007.02.001 ↗
20. 10.1002/cmdc.20140007210.1002/cmdc.201400072 ↗
21. 10.1021/ja302808p10.1021/ja302808p ↗
22. 10.1016/j.actbio.2015.11.01010.1016/j.actbio.2015.11.010 ↗
23. 10.1111/j.1751-7915.2008.00080.x10.1111/j.1751-7915.2008.00080.x ↗
24. 10.1016/j.actbio.2008.07.00210.1016/j.actbio.2008.07.002 ↗
25. 10.1002/jbm.a.3164810.1002/jbm.a.31648 ↗
26. 10.1021/bm100050d10.1021/bm100050d ↗
27. 10.1016/j.vacuum.2012.05.03110.1016/j.vacuum.2012.05.031 ↗
28. 10.1103/PhysRevB.41.319010.1103/PhysRevB.41.3190 ↗
29. 10.1155/2013/83901610.1155/2013/839016 ↗
30. 10.1016/j.matchemphys.2010.09.04910.1016/j.matchemphys.2010.09.049 ↗
31. 10.1021/acsami.6b0280310.1021/acsami.6b02803 ↗
32. 10.1126/science.362925810.1126/science.3629258 ↗
33. 10.1016/j.addr.2005.04.00710.1016/j.addr.2005.04.007 ↗
34. 10.1021/nn800596w10.1021/nn800596w ↗
35. 10.1093/cid/cir07810.1093/cid/cir078 ↗
36. ISO, Iso 10993–5: Biological Evaluationof Medical Devices - Part 5: Tests for In Vitro Cytotoxicity, (2009.
37. 10.1016/j.eurpolymj.2015.03.06610.1016/j.eurpolymj.2015.03.066 ↗
38. 10.1128/AAC.01803-1010.1128/AAC.01803-10 ↗
39. 10.1088/0957-4484/22/13/13510110.1088/0957-4484/22/13/135101 ↗
40. 10.1111/j.1365-2672.2012.05253.x10.1111/j.1365-2672.2012.05253.x ↗
41. 10.1016/j.actbio.2012.07.00510.1016/j.actbio.2012.07.005 ↗
42. 10.1021/acsami.6b0416110.1021/acsami.6b04161 ↗
43. 10.1126/scitranslmed.300627610.1126/scitranslmed.3006276 ↗
44. 10.1126/science.284.5418.131810.1126/science.284.5418.1318 ↗
45. 10.1093/jac/dku38310.1093/jac/dku383 ↗
46. 10.1021/acsami.6b1402610.1021/acsami.6b14026 ↗
47. 10.1053/ctrv.2000.018010.1053/ctrv.2000.0180 ↗
48. 10.1016/S8756-3282(02)00822-010.1016/S8756-3282(02)00822-0 ↗
49. 10.1002/cncr.2254610.1002/cncr.22546 ↗